Skip Nav Destination
Issues
1 March 2000
ISSN 1078-0432
EISSN 1557-3265
Special Lecture
Minireview
Advances in Brief
The Pathology of Familial Breast Cancer: Histological Features of Cancers in Families Not Attributable to Mutations in BRCA1 or BRCA21
Sunil R. Lakhani; Barry A. Gusterson; Jocelyne Jacquemier; John P. Sloane; Thomas J. Anderson; Marc J. van de Vijver; Deon Venter; Alex Freeman; Antonios Antoniou; Lesley McGuffog; Elizabeth Smyth; C. Michael Steel; Neva Haites; Rodney J. Scott; David Goldgar; Susan Neuhausen; Peter A. Daly; Wilma Ormiston; Ross McManus; Siegfried Scherneck; Bruce A. J. Ponder; P. Andrew Futreal; Julian Peto; Dominique Stoppa-Lyonnet; Yves-Jean Bignon; Jeffery P. Struewing; D. Timothy Bishop; J. G. M. Klijn; Peter Devilee; Cees J. Cornelisse; Christine Lasset; Gilbert Lenoir; Rosa Bjork Barkardottir; Valgardur Egilsson; Ute Hamann; Jenny Chang-Claude; Hagay Sobol; Barbara Weber; Douglas F. Easton; Michael R. Stratton
Clinical Trials
A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer
Ian Ganly; David Kirn; Susan G. Eckhardt; Gail I. Rodriguez; David S. Soutar; Randol Otto; Andrew G. Robertson; Oirhigh Park; Mark L. Gulley; Carla Heise; Daniel D. Von Hoff; Stanley B. Kaye
Suppression of Telomerase Activity and Cytokine Messenger RNA Levels in Acute Myelogenous Leukemia Cells in Vivo in Patients by Amifostine and Interleukin 41
H. D. Preisler; B. Li; J. Yang; R. W. Huang; E. Devemy; P. Venugopal; M. Tao; H. Chopra; S. A. Gregory; S. Adler; S. Sivaraman; P. Toofanfard; A. Jajeh; A. Galvez; E. Robin
Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children with Recurrent Solid Tumors after Protracted Low-Dose Irinotecan1
Margaret K. Ma; William C. Zamboni; Kristine M. Radomski; Wayne L. Furman; Victor M. Santana; Peter J. Houghton; Suzan K. Hanna; Audrey K. Smith; Clinton F. Stewart
Phase II Trial of Bryostatin 1 in Patients with Relapsed Low-Grade Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia1
Mary L. Varterasian; Ramzi M. Mohammad; Muhammad S. Shurafa; Kim Hulburd; Pamela A. Pemberton; Dorothy H. Rodriguez; Virginia Spadoni; David S. Eilender; Anthony Murgo; Nathan Wall; Maria Dan; Ayad M. Al-Katib
Experimental Therapeutics, Preclinical Pharmacology
A Wild-type Sequence p53 Peptide Presented by HLA-A24 Induces Cytotoxic T Lymphocytes that Recognize Squamous Cell Carcinomas of the Head and Neck1
Masao Eura; Kazuaki Chikamatsu; Fumihiro Katsura; Atsushi Obata; Yuji Sobao; Masafumi Takiguchi; Yongsheng Song; Ettore Appella; Theresa L. Whiteside; Albert B. DeLeo
Molecular Oncology, Markers, Clinical Correlates
Prognostic Role of Thymidylate Synthase, Thymidine Phosphorylase/ Platelet-derived Endothelial Cell Growth Factor, and Proliferation Markers in Colorectal Cancer1
Baukelien van Triest; Herbert M. Pinedo; Johannes L. G. Blaauwgeers; Paul J. van Diest; Pascale S. Schoenmakers; Daphne A. Voorn; Kees Smid; Klaas Hoekman; Henk F. W. Hoitsma; Godefridus J. Peters
Predictive Survival Markers in Patients with Surgically Resected Non-Small Cell Lung Carcinoma1
Judith Moldvay; Philippe Scheid; Pascal Wild; Karim Nabil; Joëlle Siat; Jacques Borrelly; Béatrice Marie; Guillaume Farré; Taoufik Labib; Gérard Pottier; Richard Sesboüé; Christian Bronner; Jean-Michel Vignaud; Yves Martinet; Nadine Martinet
Cancer Biology, Immunology, Cytokines
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.